Cyclodextrins as Carriers in Targeted Delivery of Therapeutic Agents: Focused Review on Traditional and Inimitable Applications

Author(s): Sushil Y. Raut, Alekhya S.N. Manne, Guruprasad Kalthur, Sanyog Jain, Srinivas Mutalik*.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 4 , 2019

Submit Manuscript
Submit Proposal

Abstract:

The objective of the article is to provide a comprehensive review on the application of cyclodextrin complexation in the delivery of drugs, bioactive molecules or macromolecules, with more emphasis on targeted drug delivery. Classically the cyclodextrins have been considered only as a means of improving the solubility of drugs; however, many attempts have been made to use cyclodextrins as drug delivery carriers. The cyclodextrin surface can be modified with various ligands for active targeting of drugs. It can also be passively targeted through various triggering mechanisms like thermal, magnetic, pH dependent, light dependent, ultrasound, etc. A comprehensive literature review has been done in the area of drug delivery using cyclodextrins. Applications of inclusion complexes in the drug delivery through various routes with examples are discussed. This review focuses on receptor mediated active targeting as well as stimuli responsive passive targeting of drugs/genes by using cyclodextrins. The article provides a detailed insight of the use of cyclodextrins and their derivatives on the targeted delivery of the drugs/genes.

Keywords: Targeted delivery, cyclodextrins, complexation, drug delivery, bioactive molecules macromolecules, drugs, gene.

[1]
Del Valle EMM. Cyclodextrins and their uses: a review. Process Biochem 2004; 39(9): 1033-46.
[2]
Conceição J, Adeoye O, Cabral-Marques HM, Lobo JMS. Cyclodextrins as excipients in tablet formulations. Drug Discov Today 2018; 23(6): 1274-84.
[3]
Higashi T, Iohara D, Motoyama K, Arima H. Supramolecular pharmaceutical sciences: a novel concept combining pharmaceutical sciences and supramolecular chemistry with a focus on cyclodextrin-based supermolecules. Chem Pharm Bull 2018; 66(3): 207-16.
[4]
Zia V, Rajewski RA, Stella VJ. Effect of cyclodextrin charge on complexation of neutral and charged substrates: comparison of (SBE)7M-beta-CD to HP-beta-CD. Pharm Res 2001; 18(5): 667-73.
[5]
Loftsson T, Hreinsdóttir D, Másson M. Evaluation of cyclodextrin solubilization of drugs. Int J Pharm 2005; 302(1-2): 18-28.
[6]
Loftsson T, Matthíasson K, Másson M. The effects of organic salts on the cyclodextrin solubilization of drugs. Int J Pharm 2003; 262(1-2): 101-7.
[7]
Jansook P, Ogawa N, Loftsson T. Cyclodextrins: structure, physicochemical properties and pharmaceutical applications. Int J Pharm 2018; 535(1-2): 272-84.
[8]
Saokham P, Muankaew C, Jansook P, Loftsson T. Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes. Molecules 2018; 23(5): E1161.
[9]
Agrawal R, Gupta V. Cyclodextrins-a review on pharmaceutical application for drug delivery. Int J Pharm Front 2012; 2(1): 95-112.
[10]
Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004; 3(12): 1023-35.
[11]
Arima H, Miyaji T, Irie T, Hirayama F, Uekama K. Enhancing effect of hydroxypropyl-β-cyclodextrin on cutaneous penetration and activation of ethyl 4-biphenylyl acetate in hairless mouse skin. Eur J Pharm Sci 1998; 6(1): 53-9.
[12]
Asai K, Morishita M, Katsuta H, et al. The effects of water-soluble cyclodextrins on the histological integrity of the rat nasal mucosa. Int J Pharm 2002; 246(1-2): 25-35.
[13]
Han Y, Liu W, Huang J, et al. Cyclodextrin-based metal-organic frameworks (CD-MOFS) in pharmaceutics and biomedicine. Pharmaceutics 2018; 10(4): 271.
[14]
Cova TF, Murtinho D, Pais AACC, Valente AJM. Combining cellulose and cyclodextrins: Fascinating designs for materials and pharmaceutics. Front Chem 2018; 6: 271.
[15]
Ahmad M, Qureshi S, Maqsood S, Gani A, Masoodi FA. Micro-encapsulation of folic acid using horse chestnut starch and β-cyclodextrin: Microcapsule characterization, release behavior & antioxidant potential during GI tract conditions. Food Hydrocoll 2017; 66: 154-60.
[16]
Santos EH, Kamimura JA, Hill LE, Gomes CL. Characterization of carvacrol beta-cyclodextrin inclusion complexes as delivery systems for antibacterial and antioxidant applications. LWT - Food Sci Technol 2015; 60(1): 583-92.
[17]
Nalawade P, Gajjar A. Assessment of in vitro bio accessibility and characterization of spray dried complex of astaxanthin with methylated betacyclodextrin. J Incl Phenom Macrocycl Chem 2015; 83(1): 63-75.
[18]
Shelley H, Babu RJ. Role of Cyclodextrins in Nanoparticle-Based Drug Delivery Systems. J Pharm Sci 2018; 107: 1741-53.
[19]
Loftsson T, Jarho P, Másson M, Järvinen T. Cyclodextrins in drug delivery. Expert Opin Drug Deliv 2005; 2(2): 335-51.
[20]
Esclusa-Diaz MT, Gayo-Otero M, Pérez-Marcos MB, Vila-Jato JL, Torres-Labandeira JJ. Preparation and evaluation of ketoconazole-β-cyclodextrin multicomponent complexes. Int J Pharm 1996; 142(2): 183-7.
[21]
Horikawa T, Hirayama F, Uekama K. In vivo and in vitro correlation for delayed-release behaviour of a molsidomine/o-carboxymethyl-o-ethyl-β-cyclodextrin complex in gastric acidity-controlled dogs. J Pharm Pharmacol 1995; 47(2): 124-7.
[22]
Horiuchi Y, Hirayama F, Uekama K. Slow-release characteristics of diltiazem from ethylated beta-cyclodextrin complexes. J Pharm Sci 1990; 79(2): 128-32.
[23]
Okimoto K, Ohike A, Ibuki R, et al. Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)7m-beta-CD. Pharm Res 1999; 16(4): 549-54.
[24]
Archontaki HA, Vertzoni MV, Athanassiou-Malaki MH. Study on the inclusion complexes of bromazepam with beta- and beta-hydroxypropyl-cyclodextrins. J Pharm Biomed Anal 2002; 28(3-4): 761-9.
[25]
Matsubara K, Abe K, Irie T, Uekama K. Improvement of nasal bioavailability of luteinizing hormone-releasing hormone agonist, buserelin, by cyclodextrin derivatives in rats. J Pharm Sci 1995; 84(11): 1295-300.
[26]
Adjei A, Sundberg D, Miller J, Chun A. Bioavailability of leuprolide acetate following nasal and inhalation delivery to rats and healthy humans. Pharm Res 1992; 9(2): 244-9.
[27]
Sakr FM. Nasal administration of glucagon combined with dimethyl-β-cyclodextrin: Comparison of pharmacokinetics and pharmacodynamics of spray and powder formulations. Int J Pharm 1996; 132(1): 189-94.
[28]
Schipper NG, Romeijn SG, Verhoef JC, Merkus FW. Nasal insulin delivery with dimethyl-β-cyclodextrin as an absorption enhancer in rabbits: powder more effective than liquid formulations. Pharm Res 1993; 10: 682-6.
[29]
Merkus FW, Verhoef JC, Marttin E, et al. Cyclodextrins in nasal drug delivery. Adv Drug Deliv Rev 1999; 36(1): 41-57.
[30]
Muankaew C, Loftsson T. Cyclodextrin-based formulations: a non-invasive platform for targeted drug delivery. Basic Clin Pharmacol Toxicol 2018; 122(1): 46-55.
[31]
Loftsson T, Stefánsson E. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. Acta Ophthalmol Scand 2002; 80(2): 144-50.
[32]
Archontaki HA, Vertzoni MV, Athanassiou-Malaki MH. Study on the inclusion complexes of bromazepam with β-and β-hydroxypropyl-cyclodextrins. J Pharm Biomed Anal 2002; 28(3-4): 761-9.
[33]
Suhonen P, Järvinen T, Lehmussaari K, Reunamäki T, Urtti A. Ocular absorption and irritation of pilocarpine prodrug is modified with buffer, polymer, and cyclodextrin in the eyedrop. Pharm Res 1995; 12: 529-33.
[34]
Järvinen T, Järvinen K, Urtti A, Thompson D, Stella VJ. Sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) in eyedrops improves the tolerability of a topically applied pilocarpine prodrug in rabbits. J Ocul Pharmacol Ther 1995; 11(2): 95-106.
[35]
Davies NM, Wang G, Tucker IG. Evaluation of a hydrocortisone/hydroxypropyl-β-cyclodextrin solution for ocular drug delivery. Int J Pharm 1997; 156(2): 201-9.
[36]
Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 2004; 3(12): 1023.
[37]
Chordiya MA, Senthilkumaran K. Cyclodextrin in drug delivery: a review. Res Rev J Pharm Pharm Sci 2012; 1: 19-29.
[38]
Arima H, Adachi H, Irie T, Uekama K. Improved drug delivery through the skin by hydrophilic β-cyclodextrins. Drug Investig 1990; 2(3): 155-61.
[39]
Tomono K, Gotoh H, Okamura M, Horioka M, Ueda H, Nagai T. Effect of β-cyclodextrins on sustained release of nitroglycerin from ointment bases. InChem. Abstr 1991; 115: 22-8.
[40]
Roy SD, de Groot JS. Percutaneous absorption of nafarelin acetate, an LHRH analog, through human cadaver skin and monkey skin. Int J Pharm 1994; 110(2): 137-45.
[41]
Ishida K, Hoshino T, Irie T, Uekama K. Alleviation of chlorpromazine-photosensitized contact dermatitis by β-cyclodextrin derivatives and their possible mechanisms. Drug Metab Pharmacokinet 1988; 3(4): 377-86.
[42]
Matsuda H, Arima H. Cyclodextrins in transdermal and rectal delivery. Adv Drug Deliv Rev 1999; 36(1): 81-99.
[43]
Takahashi T, Kagami I, Kitamura K, Nakanishi Y, Imasato Y. Stabilization of AD-1590, a non-steroidal antiinflammatory agent, in suppository bases by β-cyclodextrin complexation. Chem Pharm Bull 1986; 34: 1770-4.
[44]
Arima H, Kondo T, Irie T, Uekama K. Enhanced rectal absorption and reduced local irritation of the anti-inflammatory drug ethyl 4-biphenylylacetate in rats by complexation with water-soluble β-cyclodextrin derivatives and formulation as oleaginous suppository. J Pharm Sci 1992; 81(11): 1119-25.
[45]
Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS PharmSciTech 2005; 6(2): E329-57.
[46]
Proniuk S, Blanchard J. Anhydrous Carbopol polymer gels for the topical delivery of oxygen/water sensitive compounds. Pharm Dev Technol 2002; 7(2): 249-55.
[47]
Nagase Y, Hirata M, Wada K, et al. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether beta-cyclodextrin. Int J Pharm 2001; 229(1-2): 163-72.
[48]
Defaye J, García Fernández JM, Ortiz Mellet C. Cyclodextrins in pharmacy: prospects for targeting therapeutic assets and control of membrane interactions. Ann Pharm Fr 2007; 65: 33-49.
[49]
Bin H, Xiali L, Bo Y. Targeted drug delivery systems based on cyclodextrins. Prog Chem 2014; 26(6): 1039-49.
[50]
Bellocq NC, Pun SH, Jensen GS, Davis ME. Transferrin-containing, cyclodextrin polymer-based particles for tumor-targeted gene delivery. Bioconjug Chem 2003; 14(6): 1122-32.
[51]
Chen J, Lu S, Gu W, et al. Characterization of 9-nitrocamptothecin-in-cyclodextrin-in-liposomes modified with transferrin for the treating of tumor. Int J Pharm 2015; 490(1-2): 219-28.
[52]
Zhang H, Cai Z, Sun Y, Yu F, Chen Y, Sun B. Folate-conjugated β-cyclodextrin from click chemistry strategy and for tumor-targeted drug delivery. J Biomed Mater Res A 2012; 100: 2441-9.
[53]
Yin JJ, Sharma S, Shumyak SP, et al. Synthesis and biological evaluation of novel folic acid receptor-targeted, β-cyclodextrin-based drug complexes for cancer treatment. PLoS One 2013; 8(5): e62289.
[54]
Conte C, Fotticchia I, Tirino P, et al. Cyclodextrin-assisted assembly of PEGylated polyester nanoparticles decorated with folate. Colloids Surf B Biointerfaces 2016; 141: 148-57.
[55]
Xu J, Xu B, Shou D, Qin F, Xu Y, Hu Y. Characterization and evaluation of a folic acid receptor-targeted cyclodextrin complex as an anticancer drug delivery system. Eur J Pharm Sci 2016; 83: 132-42.
[56]
Evans JC, Malhotra M, Sweeney K, et al. Folate-targeted amphiphilic cyclodextrin nanoparticles incorporating a fusogenic peptide deliver therapeutic siRNA and inhibit the invasive capacity of 3D prostate cancer tumours. Int J Pharm 2017; 532(1): 511-8.
[57]
Yin H, Zhao F, Zhang D, Li J. Hyaluronic acid conjugated β-cyclodextrin-oligoethylenimine star polymer for CD44-targeted gene delivery. Int J Pharm 2015; 483: 169-79.
[58]
Xiong Q, Cui M, Bai Y, Liu Y, Liu D, Song T. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma. Colloids Surf B Biointerfaces 2017; 155: 93-103.
[59]
Lin IC, Fang JH, Lin CT, Sung SY, Su YL, Hu SH. Enhanced targeted delivery of cyclodextrin-based supermolecules by core-shell nanocapsules for magnetothermal chemotherapy. Macromol Biosci 2016; 16(9): 1273-86.
[60]
Saraswathy M, Knight GT, Pilla S, Ashton RS, Gong S. Multifunctional drug nanocarriers formed by cRGD-conjugated βCD-PAMAM-PEG for targeted cancer therapy. Colloids Surf B Biointerfaces 2015; 126: 590-7.
[61]
Ye Z, Zhang Q, Wang S, et al. Tumor-targeted drug delivery with mannose‐functionalized nanoparticles self-assembled from amphiphilic β-cyclodextrins. ‎. Chem Eur J 2016; 22: 15216-21.
[62]
Bertolla C, Rolin S, Evrard B, Pochet L, Masereel B. Synthesis and pharmacological evaluation of a new targeted drug carrier system: β-Cyclodextrin coupled to oxytocin. Bioorg Med Chem Lett 2008; 18(6): 1855-8.
[63]
Guo J, Ogier JR, Desgranges S, Darcy R. O′Driscoll C. Anisamide-targeted cyclodextrin nanoparticles for siRNA delivery to prostate tumours in mice. Biomaterials 2012; 33(31): 7775-84.
[64]
Evans JC, Malhotra M, Fitzgerald KA, et al. Formulation and evaluation of anisamide-targeted amphiphilic cyclodextrin nanoparticles to promote therapeutic gene silencing in a 3D prostate cancer bone metastases model. Mol Pharm 2016; 14(1): 42-52.
[65]
Guo J, Russell EG, Darcy R, et al. Antibody-targeted cyclodextrin-based nanoparticles for siRNA delivery in the treatment of acute myeloid leukemia: physicochemical characteristics, in vitro mechanistic studies, and ex vivo patient derived therapeutic efficacy. Mol Pharm 2017; 14(3): 940-52.
[66]
Huang X, Yi C, Fan Y, et al. Magnetic Fe3O4 nanoparticles grafted with single-chain antibody (scFv) and docetaxel loaded β-cyclodextrin potential for ovarian cancer dual-targeting therapy. Mater Sci Eng C 2014; 42: 325-32.
[67]
Luo C, Zuo F, Zheng Z, Ding X, Peng Y. Temperature/light dual‐responsive inclusion complexes of α‐cyclodextrins and azobenzene‐containing polymers. J Macromol Sci A 2008; 45(5): 364-71.
[68]
Song X, Wen Y, Zhu JL, Zhao F, Zhang ZX, Li J. Thermoresponsive delivery of paclitaxel by β-cyclodextrin-based poly (N-isopropylacrylamide) star polymer via inclusion complexation. Biomacromolecules 2016; 17: 3957-63.
[69]
Lu B, Wei L, Meng G, Hou J, Liu Z, Guo X. Synthesis of self-assemble pH-responsive cyclodextrin block copolymer for sustained anticancer drug delivery. Chin J Polym Sci 2017; 35(8): 924-38.
[70]
Yu H, Sun J, Zhang Y, et al. pH-and β-cyclodextrin-responsive micelles based on polyaspartamide derivatives as drug carrier. ‎. J Polym Sci A 2015; 53: 1387-95.
[71]
Bílková E, Sedlák M, Imramovský A, Chárová P, Knotek P, Beneš L. Prednisolone-α-cyclodextrin-star poly (ethylene glycol) polypseudorotaxane with delayed pH-sensitivity as a targeted drug delivery system. Int J Pharm 2011; 414(1-2): 42-7.
[72]
Mei X, Yang S, Chen D, et al. Light-triggered reversible assemblies of azobenzene-containing amphiphilic copolymer with β-cyclodextrin-modified hollow mesoporous silica nanoparticles for controlled drug release. ChemComm 2012; 48(80): 10010.
[73]
Wang A, Jin W, Chen E, Zhou J, Zhou L, Wei S. Drug delivery function of carboxymethyl-β-cyclodextrin modified upconversion nanoparticles for adamantine phthalocyanine and their NIR-triggered cancer treatment. Dalton Trans 2016; 45(9): 3853-62.
[74]
Zhang X, Ma X, Wang K, et al. Recent advances in cyclodextrin-based light-responsive supramolecular systems. Macromol Rapid Commun 2018; 39: e1800142.
[75]
Ben MA, Larue L, Moussaron A, et al. Use of cyclodextrins in anticancer photodynamic therapy treatment. Molecules 2018; 23(8): 1936.
[76]
Xu D, Wang L, Cochran S, Melzer A. Targeted drug delivery with modified gamma-cyclodextrin nanocarriers and MR-guided focused ultrasound triggering. J Ther Ultrasound 2015; 3: 79.
[77]
Gourevich D, Dogadkin O, Volovick A, et al. Ultrasound-mediated targeted drug delivery with a novel cyclodextrin-based drug carrier by mechanical and thermal mechanisms. J Control Release 2013; 170(3): 316-24.
[78]
Rahman S, Cao S, Steadman KJ, Wei M, Parekh HS. Native and β-cyclodextrin-enclosed curcumin: entrapment within liposomes and their in vitro cytotoxicity in lung and colon cancer. Drug Deliv 2012; 19(7): 346-53.
[79]
Pourjavadi A, Tehrani ZM. Poly(N-isopropylacrylamide)-coated β-cyclodextrin-capped magnetic mesoporous silica nanoparticles exhibiting thermal and pH dual response for triggered anticancer drug delivery. Int J Polym Mater Po 2017; 66(7): 336-48.
[80]
Hu QD, Tang GP, Chu PK. Cyclodextrin-based host-guest supramolecular nanoparticles for delivery: from design to applications. Acc Chem Res 2014; 47(7): 2017-25.
[81]
Nagai N, Mano Y, Ito Y. An ophthalmic formulation of disulfiram nanoparticles prolongs drug residence time in lens. Biol Pharm Bull 2016; 39(11): 1881-7.
[82]
Chen J, Yao J, Ma Z, et al. Delivery of fluorescent-labeled cyclodextrin by liposomes: role of transferrin modification and phosphatidylcholine composition. J Liposome Res 2017; 27(1): 21-31.
[83]
Badwaik V, Liu L, Gunasekera D, Kulkarni A, Thompson DH. Mechanistic insight into receptor-mediated delivery of cationic-β-cyclodextrin:hyaluronic acid-adamantamethamidyl host:guest pDNA nanoparticles to CD44+ cells. Mol Pharm 2016; 13(3): 1176-84.
[84]
Ji T, Li S, Zhang Y, et al. An MMP-2 responsive liposome integrating antifibrosis and chemotherapeutic drugs for enhanced drug perfusion and efficacy in pancreatic cancer. ACS Appl Mater Interfaces 2016; 8(5): 3438-45.
[85]
Yang Y, Zhang YM, Chen Y, Chen JT, Liu Y. Polysaccharide-based noncovalent assembly for targeted delivery of taxol. Sci Rep 2016; 6: 19212.
[86]
Chen WH, Lei Q, Luo GF, et al. Rational design of multifunctional gold nanoparticles via host-guest interaction for cancer-targeted therapy. ACS Appl Mater Interfaces 2015; 7(31): 17171-80.
[87]
Liao R, Yi S, Liu M, Jin W, Yang B. Folic acid-targeted self-assembling supramolecular carrier for gene delivery. ChemBioChem 2015; 16(11): 1622-8.
[88]
Sayed M, Pal H. pH-assisted control over the binding and relocation of an acridine guest between a macrocyclic nanocarrier and natural DNA. Phys Chem Chem Phys 2015; 17: 9519-32.
[89]
Theodossiou TA, Gonçalves AR, Yannakopoulou K, Skarpen E, Berg K. Photochemical internalization of tamoxifens transported by a “trojan-horse” nanoconjugate into breast-cancer cell lines. Angew Chem Int Ed Engl 2015; 54: 4885-9.
[90]
Shi Y, Su C, Cui W, et al. Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells. J Nanobiotechnology 2014; 12: 43.
[91]
Rodríguez-Lavado J, de la Mata M, Jiménez-Blanco JL, et al. Targeted delivery of pharmacological chaperones for Gaucher disease to macrophages by a mannosylated cyclodextrin carrier. Org Biomol Chem 2014; 12(14): 2289-301.
[92]
Zhao F, Yin H, Li J. Supramolecular self-assembly forming a multifunctional synergistic system for targeted co-delivery of gene and drug. Biomaterials 2014; 35: 1050-62.
[93]
Du F, Meng H, Xu K, et al. CPT loaded nanoparticles based on beta-cyclodextrin-grafted poly(ethylene glycol)/poly (L-glutamic acid) diblock copolymer and their inclusion complexes with CPT. Colloids Surf B Biointerfaces 2014; 113: 230-6.
[94]
Li JM, Ji YY, Mao ZW, Wang H, Zhang LN, Su ZW. Low-weight polyethylenimine cross-linked 2-hydroxypopyl-β-cyclodextrin and folic acid as an efficient and nontoxic siRNA carrier for gene silencing and tumor inhibition by VEGF siRNA. Int J Nanomedicine 2013; 8: 2101.
[95]
Gavini E, Spada G, Rassu G, et al. Development of solid nanoparticles based on hydroxypropyl-β-cyclodextrin aimed for the colonic transmucosal delivery of diclofenac sodium. J Pharm Pharmacol 2011; 63(4): 472-82.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 25
ISSUE: 4
Year: 2019
Page: [444 - 454]
Pages: 11
DOI: 10.2174/1381612825666190306163602
Price: $58

Article Metrics

PDF: 10